A generic drug is developed with the same dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use as a brand-name medication. Generics are known as bioequivalent to the name-brand drug, so they demonstrate the same degree of clinical benefit.
As millions of people all over the world get their genome sequenced, physicians and researchers as well as the individuals themselves will want to ask questions of these data. To ask question...
Wolframin is a major protein of the endoplasmic reticulum, it is expressed in most tissues and clinical data demonstrate its significant connection to diabetes mellitus. L...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
Technological advances allow for the large scale sequencing of the whole human genome. Most studies have generated population-based information on human diversity using low to intermediate co...
It is estimated that by the end of this year more than 1 million people worldwide will have had their genome sequenced. Genomic sequencing is increasingly being integrated into clinical care,...
The rapid implementation of next generation sequencing is changing how genetics and genomics are applied in a clinical setting. However, the quickly evolving technology can be challenging to...
Emerging technologies facilitate basic science research, but their value in regulatory applications requires rigorous assessment and consensus within the research community. Next-generation s...
DNASTAR offers an integrated suite of software for accurate assembly and analysis of sequence data from all major next-generation sequencing platforms supporting key workflows including de no...
We are at a time where traditionally risk-adverse health care systems and their IT architecture are confronted with the deluge of data at a massive scale and tremendous variability. In many H...
New approaches to generate high-quality representations of human genomes and transcriptomes are now becoming available. In contrast to short-read “Whole-Genome” re-sequencing meth...
Advances in DNA sequencing technology are about to transform healthcare. Since completion of the human genome reference sequence ten years ago, there has been a 1-million fold im...
It has been estimated that every human being carries ~20 rare “natural human gene knockouts”-DNA variants in protein-coding regions of the genome that partially or completely inac...
DATE: May 10th, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Cancer is a complex, multifactorial disease that not only is a cause of major human suffering throughout history...
In vitro translation (IVT) using mammalian cell extracts is a quick and convenient alternative to in vivo mammalian protein expression. Thermo Fisher has developed IVT systems from two mammal...
Complex recombinant protein biologics, such as monoclonal antibodies and coagulation factors, are key components of today’s biopharmaceutical industry. There are many effective paths fo...
The talk will focus on the recent advances in transient protein production using high cell density culture e.g. ExpiCHO, Expi293 for supporting pre-clinical and clinical studies including rob...
CHO cells are the predominant host for biotherapeutic protein expression, with roughly 70% of licensed biologics manufactured in CHO. Multiple attributes make CHO cells desirable for bi...
Reliability from gene sequence to the expressed and purified protein is essential for many aspects of basic research and drug development. Thermo Fisher Scientific’s complete portfolio ...
9:00AM PT, 11:00AM CT, 12:00PM ETThe prevalence of primary hyperaldosteronism among general and resistant hypertensive populations ranges from 5-20%. It is considered a secondary fo...
Healthcare-associated infections (HAIs) continue to be a considerable problem for hospitals and healthcare institutions that can adversely affect patient outcomes and impact the financial bot...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
As millions of people all over the world get their genome sequenced, physicians and researchers as well as the individuals themselves will want to ask questions of these data. To ask question...
Wolframin is a major protein of the endoplasmic reticulum, it is expressed in most tissues and clinical data demonstrate its significant connection to diabetes mellitus. L...
Circulating tumor cells (CTCs) is an emerging source used molecular cancer diagnostics. Through expression profiling of CTCs, it allows a deeper understanding about which metabolic pathways e...
Technological advances allow for the large scale sequencing of the whole human genome. Most studies have generated population-based information on human diversity using low to intermediate co...
It is estimated that by the end of this year more than 1 million people worldwide will have had their genome sequenced. Genomic sequencing is increasingly being integrated into clinical care,...
The rapid implementation of next generation sequencing is changing how genetics and genomics are applied in a clinical setting. However, the quickly evolving technology can be challenging to...
Emerging technologies facilitate basic science research, but their value in regulatory applications requires rigorous assessment and consensus within the research community. Next-generation s...
DNASTAR offers an integrated suite of software for accurate assembly and analysis of sequence data from all major next-generation sequencing platforms supporting key workflows including de no...
We are at a time where traditionally risk-adverse health care systems and their IT architecture are confronted with the deluge of data at a massive scale and tremendous variability. In many H...
New approaches to generate high-quality representations of human genomes and transcriptomes are now becoming available. In contrast to short-read “Whole-Genome” re-sequencing meth...
Advances in DNA sequencing technology are about to transform healthcare. Since completion of the human genome reference sequence ten years ago, there has been a 1-million fold im...
It has been estimated that every human being carries ~20 rare “natural human gene knockouts”-DNA variants in protein-coding regions of the genome that partially or completely inac...
DATE: May 10th, 2016
TIME: 8:00am Pacific time, 11:00am Eastern time
Cancer is a complex, multifactorial disease that not only is a cause of major human suffering throughout history...
In vitro translation (IVT) using mammalian cell extracts is a quick and convenient alternative to in vivo mammalian protein expression. Thermo Fisher has developed IVT systems from two mammal...
Complex recombinant protein biologics, such as monoclonal antibodies and coagulation factors, are key components of today’s biopharmaceutical industry. There are many effective paths fo...
The talk will focus on the recent advances in transient protein production using high cell density culture e.g. ExpiCHO, Expi293 for supporting pre-clinical and clinical studies including rob...
CHO cells are the predominant host for biotherapeutic protein expression, with roughly 70% of licensed biologics manufactured in CHO. Multiple attributes make CHO cells desirable for bi...
Reliability from gene sequence to the expressed and purified protein is essential for many aspects of basic research and drug development. Thermo Fisher Scientific’s complete portfolio ...
9:00AM PT, 11:00AM CT, 12:00PM ETThe prevalence of primary hyperaldosteronism among general and resistant hypertensive populations ranges from 5-20%. It is considered a secondary fo...
Healthcare-associated infections (HAIs) continue to be a considerable problem for hospitals and healthcare institutions that can adversely affect patient outcomes and impact the financial bot...
The Personalized Medicine Initiative (PMI) is a non-profit enterprise based in Vancouver, Canada that is focused on introducing personalized, molecularly-based medicine into the front lines o...
Pathology departments are under significant pressure to meet the demands of a precise medicine environment where general phenotypic attributes are no longer sufficient for accurately defining...
Cancer remains the second leading cause of death in the United States. Most tumors arise from a myriad of genetic changes that dysregulate cell growth and prompt survival. Ident...
Follow
